[go: up one dir, main page]

DK1677833T3 - Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom - Google Patents

Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom

Info

Publication number
DK1677833T3
DK1677833T3 DK04791259.7T DK04791259T DK1677833T3 DK 1677833 T3 DK1677833 T3 DK 1677833T3 DK 04791259 T DK04791259 T DK 04791259T DK 1677833 T3 DK1677833 T3 DK 1677833T3
Authority
DK
Denmark
Prior art keywords
neurturin
gene therapy
vivo gene
parkinson
disease
Prior art date
Application number
DK04791259.7T
Other languages
English (en)
Inventor
Jens Tornoe
Carl Rosenblad
Lars Wahlberg
Original Assignee
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34524307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1677833(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nsgene As filed Critical Nsgene As
Application granted granted Critical
Publication of DK1677833T3 publication Critical patent/DK1677833T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Immunology (AREA)
DK04791259.7T 2003-10-20 2004-10-20 Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom DK1677833T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301543 2003-10-20
US51291803P 2003-10-22 2003-10-22
PCT/EP2004/052586 WO2005039643A2 (en) 2003-10-20 2004-10-20 In vivo gene therapy of parkinson's disease

Publications (1)

Publication Number Publication Date
DK1677833T3 true DK1677833T3 (da) 2010-05-17

Family

ID=34524307

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04791259.7T DK1677833T3 (da) 2003-10-20 2004-10-20 Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom

Country Status (14)

Country Link
EP (2) EP1677833B1 (da)
JP (1) JP2007509109A (da)
KR (1) KR20060095568A (da)
AT (1) ATE460183T1 (da)
AU (1) AU2004283053A1 (da)
BR (1) BRPI0415563A (da)
CA (1) CA2543189A1 (da)
DE (1) DE602004025959D1 (da)
DK (1) DK1677833T3 (da)
ES (1) ES2342397T3 (da)
MX (1) MXPA06004329A (da)
NZ (1) NZ547185A (da)
RU (1) RU2006117304A (da)
WO (1) WO2005039643A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2004108760A2 (en) 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
ATE472333T1 (de) 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
JP2009513584A (ja) * 2005-10-28 2009-04-02 エヌエスゲーネ・アクティーゼルスカブ Ｇｄｎｆの送達のための移植可能な生体適合性免疫隔離ビヒクル
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
AU2008247637B2 (en) 2007-05-01 2013-12-05 Biogen Ma Inc. Compositions and methods for increasing vascularization
EP2217282A2 (en) * 2007-11-05 2010-08-18 DeveloGen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
DK3192874T3 (da) 2008-06-18 2019-12-16 Oxford Biomedica Ltd Virusoprensning
EP2493918A4 (en) * 2009-10-30 2013-04-10 Ntf Therapeutics Inc IMPROVED NEURTURINE MOLECULES
BR112013013255A2 (pt) * 2010-12-02 2020-08-25 Neurotech Usa, Inc. linhagens celulares que secretam anticorpos-esqueletos antiangiogênicos e receptores solúveis e usos das mesmas
EP2661494B1 (en) * 2011-01-07 2019-06-12 Applied Genetic Technologies Corporation Promoters, expression cassettes and vectors for use treating achromatopsia and other diseases
US9540659B2 (en) * 2012-07-06 2017-01-10 University Of Iowa Research Foundation Modified adeno-associated virus vector compositions
EP3626309B1 (en) 2012-08-13 2023-03-08 The Rockefeller University Lxrbeta agonist for the treatment of cancer
JP6109951B2 (ja) 2012-10-31 2017-04-05 ザ ロックフェラー ユニバーシティー 結腸癌の処置および診断
CN103981147B (zh) 2013-02-08 2017-11-10 中国科学院上海生命科学研究院 一种新的制备肝实质细胞的方法
AU2016256895B2 (en) 2015-05-07 2022-05-26 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
US10016514B2 (en) * 2015-05-15 2018-07-10 New Hope Research Foundation Polynucleotides, vectors and methods for insertion and expression of transgenes
WO2017081082A2 (en) * 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
JP2021512166A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物及びその使用
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof
JP7561195B2 (ja) 2020-01-29 2024-10-03 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
EP0633318A1 (en) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
EP0708670A4 (en) 1993-06-23 1998-07-01 Cytotherapeutics Inc METHOD AND APPARATUS FOR HERMETICALLY CLOSING IMPLANTABLE MEMBRANE ENCAPSULATING DEVICES
CA2169292C (en) 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US20020031493A1 (en) 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
EP1304119A3 (en) * 1997-07-30 2004-01-21 Amgen Inc. Method for preventing and treating hearing loss using a neurturin protein product
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
ES2326893T3 (es) 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6361741B1 (en) 1999-02-01 2002-03-26 Alcoa Inc. Brazeable 6XXX alloy with B-rated or better machinability
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
US6800281B2 (en) 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
US20030050273A1 (en) 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases

Also Published As

Publication number Publication date
WO2005039643A2 (en) 2005-05-06
EP1677833B1 (en) 2010-03-10
AU2004283053A1 (en) 2005-05-06
JP2007509109A (ja) 2007-04-12
KR20060095568A (ko) 2006-08-31
NZ547185A (en) 2009-03-31
EP1677833A2 (en) 2006-07-12
DE602004025959D1 (de) 2010-04-22
RU2006117304A (ru) 2007-12-10
EP2210617A1 (en) 2010-07-28
MXPA06004329A (es) 2006-06-05
CA2543189A1 (en) 2005-05-06
ES2342397T3 (es) 2010-07-06
ATE460183T1 (de) 2010-03-15
BRPI0415563A (pt) 2007-01-02
WO2005039643A3 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
WO2004022716A3 (en) Recombinatant mutants of rhabdovirus and methods of use thereof
EP1315830A4 (en) COMPOSITIONS AND METHODS RELATING TO TARGETING PEPTIDES IN IN VIVO
BE2014C077I2 (da)
WO1998049300A3 (en) Truncated vegf-related proteins
BR0207110A (pt) Pró-peptìdeos de gdf modificados e estabilizados e usos dos mesmos
AU9063801A (en) Methods and compositions for diseases associated with amyloidosis
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
WO2003024502A3 (en) Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
IL142989A (en) Nucleotide and protein sequences of nogo genes and methods based thereon
ATE457359T1 (de) Auf lps-reagierendes chs1/beige-ähnliches anker- gen und therapeutische anwendungen davon
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
DK1745069T3 (da) Terapeutisk anvendelse af vækstfaktoren NSG33
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
EP1732383A4 (en) PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
ATE529438T1 (de) Dna-sequenz und rekombinante herstellung des graspollen-allergens lol p 4
ATE394420T1 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
WO2006072601A3 (en) THERAPEUTIC USE OF GROWTH FACTORS, NsG29 AND NsG31
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2001075046A3 (fr) Nouveau polypeptide, gene humain de regulation 17 du cycle mitotique, et polynucleotide codant pour ce polypeptide
WO2001075041A3 (fr) Nouveau polypeptide, proteine humaine associee a l'epilepsie 11, et polynucleotide codant pour ce polypeptide
WO2001081538A3 (fr) Nouveau polypeptide, connexine humaine 9, et polynucleotide codant pour ce polypeptide
WO2001083687A3 (fr) Nouveau polypeptide, proteine pax humaine 23, et polynucleotide codant pour ce polypeptide
WO2001094534A3 (fr) Nouveau polypeptide, facteur humain de transcription 9.57, et polynucleotide codant ce polypeptide